Key Takeaways:
Shares of Chinese online healthcare platforms tumbled after Shanghai introduced stricter rules for purchasing popular weight-loss drugs, sparking fears of a wider crackdown that could curb a lucrative revenue stream.
"Recent market concerns over tighter regulation of GLP-1 drug sales was overdone," Nomura said in a report, arguing that the financial impact on JD Health should be manageable.
JD Health (06618.HK) plunged as much as 5.4% to an intraday low of HKD42.5 before closing at HKD42.72. Rival Ali Health (00241.HK) fell 3.3% to HKD4.1, with turnover in the two stocks reaching a combined HKD534 million. The broader Hang Seng Tech Index, which includes both companies, was also under pressure.
The sell-off erases recent gains and highlights investor sensitivity to regulatory shifts in China’s healthcare sector. While analysts believe the direct financial hit is limited, the key risk is whether Shanghai’s move is a precedent for a nationwide policy tightening on online drug sales.
The market anxiety stems from a new measure implemented in Shanghai on May 15. The city now requires patients to present a paper prescription issued by a hospital within the last three days to purchase GLP-1 drugs, a class of diabetes medication also widely used for weight loss, at offline pharmacies. This coincided with the national implementation of an updated drug administration law, fueling speculation that the restrictions could soon apply to online platforms.
Despite the sharp stock reaction, several investment banks advised the concerns are overblown. CLSA noted that online sales of GLP-1 drugs, which are classified as diabetes medication, remain unaffected for now. The broker’s view is that even if restrictions were rolled out nationally, the impact would be manageable because GLP-1 drugs account for a "relatively low proportion" of the platforms' sales.
Nomura echoed this sentiment, estimating that these drugs represent only a low single-digit percentage of JD Health's product revenue. The bank, which maintained a Buy rating on JD Health with a HKD67 price target, suggested platforms may need to make operational adjustments like halting direct "weight loss" promotions and strengthening prescription reviews, but that the financial hit would not be severe. Both JD Health and Ali Health stated they have not received any new instructions from regulators.
This article is for informational purposes only and does not constitute investment advice.
